12 Of Japan’s 13 Drug Makers Expect Higher Profits This Year
This article was originally published in PharmAsia News
All but one of Japan's 13 pharmaceutical companies are expected to see increased profits this year, according to national survey of drug makers. Only Astellas Pharma is expected to end the year lower than the year before. The survey of companies indicates they have been relatively immune to recent economic downturns. Another factor is seen in the government's schedule for reviewing drug prices, now not scheduled before April of next year. Drug makers Hisamitsu Pharmaceutical and Tsumura are expected to post double-digit profit increases this year. (Click here for more - a subscription may be required
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.